KHK

Ketohexokinase · P50053 · KHK on Sugi Atlas →

19,901 patent compounds predicted against KHK, 7,269 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2543442	1.00	20/20
SCHEMBL2546226	1.00	20/20
SCHEMBL2546575	1.00	20/20
SCHEMBL2547737	1.00	20/20
Hydrochloric Acid (SCHEMBL2545945)	0.98	20/20
Hydrochloric Acid (SCHEMBL2545303)	0.98	20/20
Hydrochloric Acid (SCHEMBL2545322)	0.98	20/20
Hydrochloric Acid (SCHEMBL2546269)	0.98	20/20
Hydrochloric Acid (SCHEMBL2546796)	0.98	20/20
Hydrochloric Acid (SCHEMBL2543444)	0.98	20/20
Hydrochloric Acid (SCHEMBL2543467)	0.98	20/20
Hydrochloric Acid (SCHEMBL2545458)	0.98	20/20
Hydrochloric Acid (SCHEMBL2545976)	0.98	20/20
Hydrochloric Acid (SCHEMBL2546602)	0.98	20/20
Hydrochloric Acid (SCHEMBL2546813)	0.98	20/20
Hydrochloric Acid (SCHEMBL2547195)	0.98	20/20
Hydrochloric Acid (SCHEMBL2545341)	0.98	20/20
Hydrochloric Acid (SCHEMBL2545701)	0.98	20/20
Hydrochloric Acid (SCHEMBL2546716)	0.98	20/20
Hydrochloric Acid (SCHEMBL2546730)	0.98	20/20

Clinical trials — most relevant to KHK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Exogenous Ketone Esters for Refractory Status Epileptics	PHASE2/PHASE3	RECRUITING
Reappraisal of GIK in Acute STEMI by Pre-hospital Administration	PHASE3	UNKNOWN
Ketohexokinase Inhibition in Hereditary Fructose Intolerance	PHASE2	COMPLETED
Ketohexokinase Inhibition in NAFLD	PHASE2	COMPLETED
To Assess Safety of Mitapivat and Provide Proof of Concept of the Efficacy of the Drug in Patients With RBC Membranopathies or CDAII.	PHASE2	RECRUITING
Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome	PHASE2	UNKNOWN
Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation.	PHASE1/PHASE2	NOT_YET_RECRUITING
Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique	PHASE2	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Multi-Tracer PET Assessment of Primary Brain Tumors	PHASE1	COMPLETED
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride	PHASE1	COMPLETED
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus	PHASE1	COMPLETED
A Dose-Finding Study of AG-348 in Sickle Cell Disease	EARLY_PHASE1	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction	nan	ACTIVE_NOT_RECRUITING
Dietary Strategies for the Treatment of Fibromyalgia in Overweight and Obese Patients	nan	NOT_YET_RECRUITING
Effect of Acute Fructose Load in Human	nan	COMPLETED
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Evaluation of the Ketogenic Diet to Improve Post Operative Cognitive Decline in Cardiac Surgery	nan	WITHDRAWN
Effects of Urinary Kallidinogenase in Acute Ischemic Stroke Patients With Abnormal Glucose Metabolism	nan	COMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours	nan	RECRUITING
A Glucometabolic Evaluation of Patients With Idiopathic Ketotic Hypoglycemia	nan	UNKNOWN
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test	nan	COMPLETED
The Effect of Ketone Esters on Forearm Glucose Metabolism	nan	ACTIVE_NOT_RECRUITING
Alternative Substrates in the Critically Ill Subject	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KHK binder may also engage these)

Protein	Name	Similarity
Q02974	—	1.000	Q02974 →
P97328	—	1.000	P97328 →
Q5RD71	—	0.998	Q5RD71 →
Q8K183	—	0.961	Q8K183 →
O35331	—	0.960	O35331 →
PDXK	Pyridoxal kinase	0.954	landscape →
O46560	—	0.951	O46560 →
Q8R238	—	0.950	Q8R238 →
A0A6N3IN21	—	0.946	A0A6N3IN21 →
Q4V9J0	—	0.944	Q4V9J0 →
P24298	—	0.943	P24298 →
Q5R514	—	0.942	Q5R514 →
P82197	—	0.941	P82197 →
Q6AYR6	—	0.941	Q6AYR6 →
A4IFH5	—	0.940	A4IFH5 →
Q5BJJ5	—	0.940	Q5BJJ5 →
Q8QZR5	—	0.940	Q8QZR5 →
Q9QZ08	—	0.940	Q9QZ08 →
Q9Y5N5	—	0.939	Q9Y5N5 →
Q9UJ70	—	0.939	Q9UJ70 →
Q2KIU2	—	0.939	Q2KIU2 →
Q3UGR5	—	0.938	Q3UGR5 →
E1BNQ4	—	0.938	E1BNQ4 →
Q0II59	—	0.938	Q0II59 →
Q8VBT2	—	0.938	Q8VBT2 →
Q96GA7	—	0.937	Q96GA7 →
P13439	—	0.937	P13439 →
Q3SZM9	—	0.937	Q3SZM9 →
UMPS	Uridine 5'-monophosphate synthase	0.937	landscape →
Q8HZJ0	—	0.937	Q8HZJ0 →